Filing Details

Accession Number:
0001179110-18-002113
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-14 18:12:21
Reporting Period:
2018-02-12
Accepted Time:
2018-02-14 18:12:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1229450 A Craig Wheeler C/O Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge MA 02142
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-02-12 1,773 $16.18 258,713 No 4 S Direct
Common Stock Disposition 2018-02-14 16,875 $16.14 241,838 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2018-02-12 98,750 $0.00 98,750 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2018-02-12 197,500 $0.00 197,500 $16.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
98,750 No 4 A Direct
197,500 2028-02-12 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 329,324 Indirect Craig Wheeler Revocable Trust
Common Stock 45,980 Indirect Craig A Wheeler 2016 Annuity Trust
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person June 13, 2016.
  2. This transaction was executed in multiple trades at prices ranging from $16.05 to $16.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 1, 2016.
  4. This transaction was executed in multiple trades at prices ranging from $15.15 to $16.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock.
  6. Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.
  7. Subject to certain criteria, the stock options will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.